Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg once weekly in obesity with prediabetes
2020-002939-29Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity and prediabetes comparing Semaglutide 2.4 mg once weekly with Placebo once weekly (2 arms). Primary endpoints: Change in body weight and Reversal to normoglycemia. Started May 2021; status: completed.
02
Drugs
03
Conditions
obesityprediabetes
Beyond the preview
Go deeper on 2020-002939-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002939-29.